These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4837137)

  • 1. A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer.
    Kovach JS; Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Oncology; 1974; 29(1):34-9. PubMed ID: 4837137
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
    Bremner DN; McCormick JS; Thomson JW
    Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical pharmacology of isophosphamide.
    Creaven PJ; Allen LM; Alford DA; Cohen MH
    Clin Pharmacol Ther; 1974 Jul; 16(1):77-86. PubMed ID: 4602057
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunosuppressive properties of cyclophosphamide analogues.
    Harrison EF; Fuquay ME
    Proc Soc Exp Biol Med; 1972 Mar; 139(3):957-63. PubMed ID: 5063370
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.
    O'Connell TX; Berenbaum MC
    Cancer Res; 1974 Jul; 34(7):1586-91. PubMed ID: 4833912
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal dysfunction after treatment with isophosphamide (NSC-109724).
    DeFronzo RA; Abeloff M; Braine H; Humphrey RL; Davis PJ
    Cancer Chemother Rep; 1974; 58(3):375-82. PubMed ID: 4842666
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.
    Bruno S; Creaven PJ; Ledesma E; Poster D; Yoon J; Mittelman A
    Am J Clin Oncol; 1982 Feb; 5(1):69-71. PubMed ID: 7081140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative study of cyclophosphamide, ifosfamide and trofosfamide on Walker-256 carcinosarcoma in embryonated chicken eggs].
    Norpoth K; Witting U; Rauen HM
    Arzneimittelforschung; 1974 Jan; 24(1):86-9. PubMed ID: 4406116
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
    Abele R; Alberto P; Kaplan S; Siegenthaler P; Hofmann V; Ryssel HJ; Hartmann D; Holdener EE; Cavalli F
    J Clin Oncol; 1983 Dec; 1(12):750-4. PubMed ID: 6230419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected toxicity in patients treated with iphosphamide.
    Van Dyk JJ; Falkson HC; Van der Merwe AM; Falkson G
    Cancer Res; 1972 May; 32(5):921-4. PubMed ID: 4552918
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
    Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
    Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of chromomycin A3 (NSC-58514) in advanced colorectal carcinoma.
    Moertel CG; Schutt AJ; Hahn RG; Marciniak TA; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(3):577-9. PubMed ID: 1203884
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of mitoxantrone in advanced colorectal cancer.
    Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
    Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
    Rubin J; van Hazel GA; Schutt AJ; Moertel CG; O'Connell MJ
    Am J Clin Oncol; 1982 Oct; 5(5):539-40. PubMed ID: 7180832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of maytansine in patients with advanced colorectal carcinoma.
    O'Connell MJ; Shani A; Rubin J; Moertel CG
    Cancer Treat Rep; 1978 Aug; 62(8):1237-8. PubMed ID: 356981
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of pyrazofurin in advanced colorectal carcinoma.
    Creagan ET; Rubin J; Moertel CG; Schutt AJ; O'connell MJ; Hahn RG; Reitemeir RJ; Frytak S
    Cancer Treat Rep; 1977; 61(3):491-3. PubMed ID: 872147
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
    Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
    Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 2 study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer.
    Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Cancer Res; 1973 Oct; 33(10):2218-20. PubMed ID: 4741927
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Feb; 56(1):95-101. PubMed ID: 5030811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.